⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
IDE034, un anticuerpo conjugado a fármaco biespecífico cuya licencia fue otorgada por Biocytogen a IDEAYA, recibe la autorización de nuevo fármaco en investigación de la FDA
businesswire.com
IDYA
IDE034, un CAM bispécifique dont la licence est octroyée par Biocytogen à IDEAYA, vient de recevoir l'approbation IND de la FDA
businesswire.com
IDYA
百奧賽圖授權IDEAYA的雙抗ADC專案IDE034獲FDA IND核准，合作取得關鍵里程碑進展
businesswire.com
IDYA
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
businesswire.com
IDYA
百奥赛图授权IDEAYA的双抗ADC项目IDE034获FDA IND批准，合作取得关键里程碑进展
businesswire.com
IDYA
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
businesswire.com
IDYA
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
prnewswire.com
IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
prnewswire.com
IDYA
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
businesswire.com
QTRX
TMO
ILMN
IDYA
MTD
IR
TROW
EXAS
SERA